Rakuten Securities Inc. Invests $46,000 in Catalent, Inc. (NYSE:CTLT)

Rakuten Securities Inc. bought a new position in Catalent, Inc. (NYSE:CTLT) during the 4th quarter, HoldingsChannel.com reports. The fund bought 1,021 shares of the company’s stock, valued at approximately $46,000.

Several other institutional investors have also made changes to their positions in CTLT. Thompson Siegel & Walmsley LLC lifted its stake in Catalent by 46.6% in the third quarter. Thompson Siegel & Walmsley LLC now owns 704,322 shares of the company’s stock valued at $32,069,000 after acquiring an additional 223,944 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Catalent by 1.8% in the third quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock worth $931,909,000 after buying an additional 365,648 shares during the last quarter. Tran Capital Management L.P. lifted its stake in shares of Catalent by 12.2% in the fourth quarter. Tran Capital Management L.P. now owns 361,846 shares of the company’s stock worth $16,258,000 after buying an additional 39,208 shares during the last quarter. Hsbc Holdings PLC lifted its stake in shares of Catalent by 43.1% in the third quarter. Hsbc Holdings PLC now owns 193,322 shares of the company’s stock worth $8,803,000 after buying an additional 58,240 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in shares of Catalent by 240.0% in the fourth quarter. SG Americas Securities LLC now owns 40,249 shares of the company’s stock worth $1,808,000 after buying an additional 28,410 shares during the last quarter.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on CTLT shares. Royal Bank of Canada restated a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, February 20th. Barclays boosted their price objective on shares of Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a research note on Thursday, January 25th. UBS Group restated a “neutral” rating and issued a $63.50 price objective (up from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Stephens restated an “equal weight” rating and issued a $63.50 price objective on shares of Catalent in a research note on Thursday, April 4th. Finally, StockNews.com started coverage on shares of Catalent in a research report on Friday. They set a “sell” rating on the stock. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Catalent currently has an average rating of “Hold” and a consensus price target of $52.46.

Catalent Trading Down 0.3 %

CTLT opened at $55.77 on Friday. The firm’s 50-day simple moving average is $56.83 and its 200-day simple moving average is $48.16. The company has a quick ratio of 1.73, a current ratio of 2.48 and a debt-to-equity ratio of 1.34. Catalent, Inc. has a twelve month low of $31.45 and a twelve month high of $60.20.

Catalent (NYSE:CTLT) last posted its earnings results on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.22). The firm had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.01 billion. Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The firm’s revenue for the quarter was down 10.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.62 EPS. As a group, sell-side analysts forecast that Catalent, Inc. will post 0.28 EPS for the current fiscal year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.